Dong MA | Cardiovascular Researches | Best Researcher Award

Prof. Dong MA | Cardiovascular Researches | Best Researcher Award

Prof. Dong MA, Hebei Medical University, China

Prof. Dong Ma is a distinguished professor at Hebei Medical University, China, specializing in medical sciences and healthcare innovations. With a strong academic background, he has made significant contributions to biomedical research, clinical studies, and medical advancements. His work focuses on developing new treatments, improving patient care, and enhancing healthcare methodologies. Prof. Ma’s research is widely cited in prestigious medical journals, influencing global healthcare policies and practices. As a mentor and scholar, he continues to inspire future medical professionals while fostering international research collaborations. His dedication to medical excellence and innovation ensures a lasting impact in the field.

AUTHOR PROFILE

Scopus Profile

šŸŽ“ EARLY ACADEMIC PURSUITS:

Prof. Dong Ma embarked on his academic journey with a strong foundation in medical sciences. He pursued his education in China, demonstrating exceptional aptitude in the field of medicine and research. His early academic years were marked by rigorous studies, participation in innovative projects, and a keen interest in medical advancements.

šŸ›ļø PROFESSIONAL ENDEAVORS:

Prof. Ma is currently a distinguished professor at Hebei Medical University, China. Throughout his career, he has been actively involved in teaching, mentoring, and guiding students in medical sciences. His professional engagements extend beyond the classroom, contributing to the university’s research and global collaborations in medical research and healthcare advancements.

šŸ”¬ CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCHES:

Prof. Maā€™s research primarily revolves around medical sciences, healthcare innovations, and clinical applications. His work includes:

  • Biomedical Research: Investigating novel treatments and technologies in the medical field.
  • Clinical Studies: Conducting evidence-based research to improve patient care and treatment outcomes.
  • Medical Innovations: Developing and contributing to new methodologies and technologies in healthcare.

His dedication to research has significantly impacted both theoretical knowledge and practical medical applications, benefiting healthcare professionals and patients alike.

šŸŒ IMPACT AND INFLUENCE:

Prof. Ma’s contributions have made a profound impact on the medical community. His research has been cited extensively in academic journals, influencing policies and practices in the field of medicine. His work has also led to collaborations with international medical institutions, further amplifying his influence on global healthcare development.

šŸ“– ACADEMIC CITATIONS:

Prof. Ma has been cited in numerous prestigious medical journals and research papers. His publications cover a wide range of topics, including:

  • Advances in medical treatments and techniques.
  • Healthcare policy improvements.
  • Breakthroughs in disease prevention and management.

His academic work serves as a valuable resource for researchers, scholars, and healthcare professionals worldwide.

šŸ… LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Dong Maā€™s legacy is built upon his relentless pursuit of medical excellence. His future contributions are expected to:

  • Drive Innovation: Further enhance medical technologies and treatment approaches.
  • Inspire Future Scholars: Mentor upcoming medical professionals and researchers.
  • Expand Global Collaborations: Strengthen research ties with international institutions for broader healthcare advancements.

šŸ”„ CONCLUSION:

Prof. Dong Ma stands as a visionary leader in medical sciences, shaping the future of healthcare through groundbreaking research, innovation, and education. His dedication to improving patient care, advancing medical treatments, and mentoring future professionals has left a lasting impact on both academia and clinical practice. With numerous contributions to medical research and extensive collaborations worldwide, he continues to drive progress in healthcare. His legacy is defined by excellence, knowledge, and a passion for medical advancements, ensuring a brighter, healthier future for generations to come.

TOP NOTABLE PUBLICATIONS

The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral,Non-Alcoholic Hepatocellular Carcinoma:a Retrospective Cohort Study

Authors: Xianzhe Lou, Tongguo Miao, Shiya Zhang, Dong Ma, Yuemin Nan

Journal: Chinese General Practice

Year: 2025

Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma

Authors: Tongguo Miao, Shiya Zhang, Yunjing Zhang, Dong Ma, Yuemin Nan

Journal: Scientific Reports

Year: 2024

Study on the relationship between Methylation of Neuregulin (NRG) Gene and Cervical Carcinoma

Authors: Xizhao Yan, Fenglan An, Zhenzhen Ding, Dong Ma, Xiaohui Yang

Journal: Pakistan Journal of Medical Sciences

Year: 2024

Ī±-HBDH is a superior to LDH in predicting major adverse cardiovascular events in patients with acute aortic dissection

Authors: Yunjing Zhang, Yue Sun, Yongbo Zhao, Dong Ma

Journal: Heliyon

Year: 2024

Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease

Authors: Tongguo Miao, Xianzhe Lou, Shiming Dong, Dong Ma, Yuemin Nan

Journal: Journal of Hepatocellular Carcinoma

Year: 2024

Sara Kaveh | Hypercholesterolemia | Best Researcher Award

Ms. Sara Kaveh | Hypercholesterolemia | Best Researcher Award

Ms. Sara Kaveh, Tehran University of Medical Sciences, Iran

Ms. Sara Kaveh is a dedicated researcher and academic affiliated with Tehran University of Medical Sciences, Iran. Her work focuses on advancing medical research and education within the field of health sciences. She has contributed to various projects aimed at improving healthcare outcomes and is recognized for her commitment to scientific excellence and innovation.

Profile:
Education:

Ms. Sara Kaveh is a PhD candidate in Health Economics at Tehran University of Medical Sciences, where her dissertation explores regionalization models for pancreaticoduodenectomy in Iran, focusing on outcomes and costs. She earned her M.Sc. in Health Technology Assessment from Iran University of Medical Sciences, with a dissertation comparing bevacizumab and its combination with erlotinib for metastatic colorectal cancer. Earlier, she completed an M.Sc. in Health Information Technology at Kerman University of Medical Sciences, investigating the use of the Internet for health information among academic professionals. Her work integrates health economics and technology assessment to enhance healthcare delivery and policy.

ProfessionalĀ  Experience:

 

Ms. Sara Kaveh is currently a Research Assistant at Shiraz University of Medical Sciences, a role she began in November 2023, building on her previous tenure at the same institution from August 2019 to August 2021. From June 2017 to August 2019, she worked as an independent researcher, leading multidisciplinary teams and publishing extensively in high-impact journals. Her research spans health economics and technology assessment, contributing significantly to the academic and practical understanding of healthcare improvements.

Honors and Awards:

Ms. Sara Kaveh achieved notable academic distinctions, securing 4th place in the highly competitive Ph.D. entrance exam in Iran and 6th place in the M.Sc. entrance exam. These rankings underscore her exceptional academic capabilities and commitment to excellence in her field of health economics and technology assessment.

Top Notable Publications:

Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic Review

Journal: Current Therapeutic Research

Date: September 2024

DOI: 10.1016/j.curtheres.2024.100758

Telehealth impact on biomedical, psychosocial, and behavioural outcomes in patients with diabetes older than 50 years: A systematic synthesis without meta-analysis

Journal: Journal of Telemedicine and Telecare

Date: February 2024

DOI: 10.1177/1357633X211052222

Clinical Characteristics, Laboratory Features, and Outcomes of 151 Pediatric Patients with COVID-19 and MIS-C: A Single-center Study in the Northwest of Iran

Journal: Archives of Pediatric Infectious Diseases

Date: May 7, 2023

DOI: 10.5812/pedinfect-132819

Mobile Health-Based Interventions in Self-care and Treatment Adherence in Older People: A Review Study

Journal: International Journal of Aging

Date: April 27, 2023

DOI: 10.34172/ija.2023.e6

Prevention of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis

Journal: International Journal of Clinical Pharmacy

Date: 2021

DOI: 10.1007/S11096-020-01146-6

WOSUID: WOS:000568149400001

Comparing cardiac troponin levels using sevoflurane and isoflurane in patients undergoing cardiac surgery: a systematic review and meta-analysis

Journal: Journal of Cardiovascular and Thoracic Research

Date: February 12, 2020

DOI: 10.34172/jcvtr.2020.01

Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis

Journal: Clinical Rheumatology

Date: 2020

DOI: 10.1007/S10067-020-04948-1

WOSUID: WOS:000531129700001

Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis

Journal: International Journal of Clinical Pharmacy

Date: 2019

DOI: 10.1007/S11096-018-0754-1

WOSUID: WOS:000458652000008

Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis

Journal: International Journal of Clinical Pharmacy

Date: 2019

DOI: 10.1007/S11096-018-00778-Z

WOSUID: WOS:000458652000007

Health technology assessment of Bevacizumab compare with combination of Bevacizumab with Erlotinib for treatment of patients with metastatic colorectal cancer

DOI: 10.22037/IPA.V1I1.20015

The Efficacy of Ivabradine versus Beta Blockers in Comparison of Atenolol and Metoprolol in Patients with Mitral Stenosis in Sinus Rhythm: A Systematic Review and Meta-Analysis

DOI: 10.22037/IPA.V1I1.20006